Concourse Financial Group Securities, Inc. Theseus Pharmaceuticals, Inc. Transaction History

Concourse Financial Group Securities, Inc.

$1.56 Billion
Q2 2024

10 transactions

Quarter	Operation	Price Per share
Q4 2023 Feb 07, 2024	BUY	$2.12 - $4.18 $0 - $0
Q3 2023 Oct 30, 2023	BUY	$2.66 - $10.04 $0 - $0
Q3 2023 Oct 25, 2023	BUY	$2.66 - $10.04 $0 - $0
Q2 2023 Aug 10, 2023	BUY	$7.28 - $11.82 $0 - $0
Q1 2023 May 15, 2023	BUY	$5.21 - $14.05 $0 - $0
Q4 2022 Jan 30, 2023	BUY	$4.69 - $8.36 $0 - $0
Q3 2022 Nov 15, 2022	BUY	$5.7 - $8.68 $0 - $0
Q2 2022 Aug 09, 2022	BUY	$5.04 - $14.05 $0 - $0
Q1 2022 May 09, 2022	BUY	$8.75 - $14.51 $0 - $0
Q4 2021 Feb 07, 2022	BUY	$8.98 - $20.09 $0 - $0

Others Institutions Holding THRX

# of Institutions

Shares Held

1.03M

Call Options Held

Put Options Held

View Full List

About Theseus Pharmaceuticals, Inc.

Ticker THRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,713,400
Description
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also ...

More about THRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account